Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BXL 628; Vitamin D3 analogue - BioXell

Latest Information Update: 30 Dec 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer BioXell SpA; Cosmo Pharmaceuticals
  • Class Dihydroxycholecalciferols; Small molecules; Urologics; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Intercellular signalling peptide and protein inhibitors; Interleukin 8 inhibitors; Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Male infertility
  • Discontinued Benign prostatic hyperplasia; Interstitial cystitis; Overactive bladder; Prostatitis

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 08 Apr 2009 Top-line efficacy data from a Phase-IIb trial in Overactive bladder released by BioXell SpA
  • 17 Dec 2008 BioXell SpA completes enrolment in its Phase-IIb trial for Overactive bladder in the EU and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top